|1.||Wang, Qin: 3 articles (12/2013 - 01/2011)|
|2.||Taioli, Emanuela: 3 articles (04/2009 - 05/2003)|
|3.||Zheng, Wei: 3 articles (07/2008 - 09/2004)|
|4.||Lu, Wei: 3 articles (07/2008 - 01/2006)|
|5.||Tamer, Lülüfer: 3 articles (10/2006 - 04/2005)|
|6.||Wolf, Andrea: 2 articles (12/2015 - 11/2015)|
|7.||Watrowski, Rafał: 2 articles (12/2015 - 11/2015)|
|8.||Schuster, Eva: 2 articles (12/2015 - 11/2015)|
|9.||Castillo-Tong, Dan Cacsire: 2 articles (12/2015 - 11/2015)|
|10.||Speiser, Paul: 2 articles (12/2015 - 11/2015)|
09/01/2010 - "We observed that GSTM1 and GSTT1 null genotype frequencies were 54.3% and 32.6% respectively, while GSTP1 (Ile/Val), (Ile/Ile), (Val/Val) genotype frequencies were 52%, 44%, and 4%, respectively, in the cervical cancer patients. "
05/01/2006 - "Half of the eight ovarian tumor patients carried heterozygous Ile/Val genotypes. "
04/15/2006 - "It is thus concluded that cervical cancer risk is increased in passive smokers with GSTM1 (null), GSTT1 (null), and GSTP1 (ile/val) genotypes."
01/01/2012 - "In the stratified analyses, there was a significantly increased cancer risk among African (Val/Val vs. Ile/Ile OR = 2.19, 95% CI = 1.29-3.73, P(heterogeneity) = 0.989; Ile/Val + Val/Val vs. Ile/Ile: OR = 1.79, 95%CI = 1.18-2.71, P(heterogeneity) = 0.761; Val/Val vs. Ile/Val + Ile/Ile: OR = 1.92, 95% CI = 1.16-3.17, P(heterogeneity) = 0.981) and Asian (Ile/Val vs. Ile/Ile: OR = 1.58, 95% CI = 1.32-1.90, P(heterogeneity) = 0.375; Val/Val vs. Ile/Ile: OR = 3.84, 95% CI = 1.74-8.49, P(heterogeneity) = 0.160; Ile/Val + Val/Val vs. Ile/Ile: OR = 1.65, 95% CI = 1.38-1.96, P(heterogeneity) = 0.330; Val/Val vs. Ile/Val + Ile/Ile: OR = 3.54, 95% CI = 1.62-7.75, P(heterogeneity) = 0.154) studies. "
08/01/2014 - "Logistic regression analysis adjusting for age, parity, oral contraceptive use, tobacco smoking, and menopausal status demonstrated that that the CYP1A1 Ile/Val polymorphism was not associated with an increased risk of cervical cancer in all patients. "
01/01/1980 - "The continuous administration of physiological doses of the branched-chain amino acids leucine, isoleucine, and valine (Leu-Ile-Val) to Yoshida sarcoma-bearing rats caused a significant increase in the survival time by 32% and a significant reduction of tumor size after 3 weeks of growth by 33%. "
|3.||Lung Neoplasms (Lung Cancer)
08/01/2015 - "The aim of the study was to assess the expression and significance of HER2 and HER3, and Ile/Val single nucleotide polymorphism (SNP) of HER2 in lung cancer patients. "
01/01/1995 - "The apparent lack of association of CypIA1 MspI polymorphism with lung cancer in this area reported in our previous study and the results of the present study indicate that the "true" responsible site for lung cancer susceptibility should be the Ile-Val polymorphism in the catalytic site of CypIA1."
05/01/2011 - "In a combined analysis, the summary per-allele odds ratios for lung cancer of the MspI and Ile-Val polymorphism were 1.19 [95% confidence interval (CI): 1.11-1.28] and 1.20 (95% CI: 1.08-1.33), respectively. "
01/01/2001 - "Three polymorphisms, m1 (MSP:I), m2 (exon 7 Ile-->Val) and m4 (exon 7 Thr-->Asn), were determined by PCR-RFLP in 404 controls and 217 lung cancer cases. "
03/01/2000 - "The odds ratio of lung cancer associated with the Ile-Val combined variant and homozygous genotypes were 1.16 (0.92-1.48) and 1.62 (0.93-2.82), respectively. "
|4.||Esophageal Neoplasms (Esophageal Cancer)
11/01/2009 - "To examine the association between CYP1A1 polymorphisms (MspI and Ile/Val) and esophageal cancer (EC) by systematically reviewing the risk of the original studies. "
10/01/2014 - "These results suggested that the CYP1A1 Ile/Val polymorphism was associated with an increased risk of esophageal cancer, whereas the CYP1A1 MspI polymorphism may not have increased susceptibility to esophageal cancer. "
10/01/2014 - "The subgroup analysis based on ethnicity showed that the association between the CYP1A1 Ile/Val polymorphism and esophageal cancer existed in Asian and Caucasian populations. "
01/01/2014 - "For the CYP1A1 Ile/Val polymorphism, comparing with wild genotype Ile/Ile, both the heterozygote genotype Ile/Val and the combined variant genotype Ile/Val+Val/Val increased the risk of esophageal cancer (OR: 2.05, 95%CI: 1.19-3.54, OR: 1.86, 95%CI: 1.11-3.12). "
11/01/2009 - "Data from 16 papers (8 for MspI, 14 for Ile/Val) regarding case-control studies on the association of cytochrome P450 polymorphisms and risk of esophageal cancer was analyzed by dominant model (variant genotype vs. wild-type genotype) through meta-analysis. "
|5.||Gallbladder Neoplasms (Gallbladder Cancer)
03/01/2002 - "This study demonstrated a significant over-representation of genotypes C and Ile/Val in female patients with gallbladder cancer. "
05/01/2006 - "To best of our knowledge, this is the first paper showing ile/val genotypes and val allele of GSTP1 to be associated with higher risk of gallbladder cancer."
03/01/2002 - "Females with genotypes C and/or Ile/Val may have a high genetic susceptibility to the development of gallbladder cancer."
05/01/2006 - "To study gene-gene interactions, a combined risk of gallbladder cancer due to ile/val or val/val were calculated in combination with null alleles of GSTM1 and GSTT1 or the *B allele of GSTM3, but there was no enhancement of risk. "
03/01/2002 - "To clarify individual differences in susceptibility to gallbladder carcinogenesis, we investigated the frequency of the Mspl and Ile-Val polymorphisms of the CYP1A1 gene, in 52 patients with gallbladder cancer (32 females, 20 males) and 104 healthy controls (64 females, 40 males). "
|4.||Branched-Chain Amino Acids
|5.||Cytochrome P-450 CYP1A1 (CYP1A1)
|7.||Cytochrome P-450 Enzyme System (Cytochrome P450)
|10.||DNA (Deoxyribonucleic Acid)